Karin M Danzer

List of Publications by Year
in descending order

63 papers	6,187 citations	136950 32 h-index	123424 61 g-index
64 all docs	64 docs citations	64 times ranked	8631 citing authors

#	Article	IF	Citations
1	Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells. Neurobiology of Aging, 2022, 116, 16-24.	3.1	8
2	Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients. Acta Neuropathologica, 2022, 144, 161-164.	7.7	1
3	Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43 transgenic mice. Experimental Neurology, 2021, 335, 113496.	4.1	15
4	Protein Binding Partners of Dysregulated miRNAs in Parkinsonâ€™s Disease Serum. Cells, 2021, 10, 791.	4.1	11
5	A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis. Brain, 2021, 144, 1214-1229.	7.6	8
6	T-cell dysregulation is associated with disease severity in Parkinsonâ€™s Disease. Journal of Neuroinflammation, 2021, 18, 250.	7.2	22
7	SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden. Neurobiology of Aging, 2020, 87, 139.e9-139.e15.	3.1	23
8	The Role of Lipids in the Initiation of Î±-Synuclein Misfolding. Frontiers in Cell and Developmental Biology, 2020, 8, 562241.	3.7	29
9	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. Journal of Virological Methods, 2020, 286, 113965.	2.1	10
10	Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Communications, 2020, 2, fcaa133.	3.3	9
11	Intracellular Alpha-Synuclein and Immune Cell Function. Frontiers in Cell and Developmental Biology, 2020, 8, 562692.	3.7	13
12	Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N. Neuroscience, 2020, 441, 33-45.	2.3	8
13	Increased Immune Activation by Pathologic Î±â€Synuclein in Parkinson's Disease. Annals of Neurology, 2019, 86, 593-606.	5.3	95
14	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
15	Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. Journal of Experimental Medicine, 2019, 216, 267-278.	8.5	57
16	Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model. Translational Neurodegeneration, 2019, 8, 27.	8.0	13
17	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	6.4	26
18	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167

#	Article	IF	Citations
19	Release and uptake of pathologic alpha-synuclein. Cell and Tissue Research, 2018, 373, 175-182.	2.9	57
20	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Human Molecular Genetics, 2018, 27, 706-715.	2.9	30
21	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cellular and Molecular Life Sciences, 2018, 75, 4301-4319.	5.4	34
22	Age Increases Monocyte Adhesion on Collagen. Scientific Reports, 2017, 7, 46532.	3.3	10
23	ALS-causing mutations differentially affect PGC-1Î± expression and function in the brain vs. peripheral tissues. Neurobiology of Disease, 2017, 97, 36-45.	4.4	35
24	Impaired activation of ALS monocytes by exosomes. Immunology and Cell Biology, 2017, 95, 207-214.	2.3	39
25	Proteasome impairment by Î±-synuclein. PLoS ONE, 2017, 12, e0184040.	2.5	49
26	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (Î±-syn) oligomerization and secretion. Aging, 2017, 9, 1677-1697.	3.1	7
27	LRRK2 contributes to monocyte dysregulation in Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 123.	5.2	29
28	Aggregated Î±-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	3.8	17
29	Induction of Î±-synuclein aggregate formation by CSF exosomes from patients with Parkinsonâ€™s disease and dementia with Lewy bodies. Brain, 2016, 139, 481-494.	7.6	349
30	Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathologica, 2016, 131, 379-391.	7.7	140
31	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathologica, 2016, 132, 391-411.	7.7	116
32	NEK1mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	7.6	105
33	Screening forCHCHD10mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant: Table 1. Brain, 2016, 139, e8-e8.	7.6	20
34	Telomere shortening leads to earlier age of onset in ALS mice. Aging, 2016, 8, 382-393.	3.1	31
35	Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. Journal of Neurology and Neuromedicine, 2016, 1, 28-30.	0.9	9
36	The Golgi-Localized Î³-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-Î² Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). PLoS ONE, 2015, 10, e0129047.	2.5	17

#	Article	IF	Citations
37	Î±-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration, 2015, 10, 66.	10.8	29
38	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	3.1	64
39	Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy. Analytical and Bioanalytical Chemistry, 2015, 407, 4015-4021.	3.7	20
40	Extracellular vesicle sorting of Î±-Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
41	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
42	TDP-43 is intercellularly transmitted across axon terminals. Journal of Cell Biology, 2015, 211, 897-911.	5.2	263
43	Mutual exacerbation of peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± deregulation and Î±â€synuclein oligomerization. Annals of Neurology, 2015, 77, 15-32.	5.3	112
44	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not Î±-Synuclein-Induced Neuronal Cell Loss. PLoS ONE, 2014, 9, e86048.	2.5	35
45	Inflammatory dysregulation of blood monocytes in Parkinsonâ€™s disease patients. Acta Neuropathologica, 2014, 128, 651-663.	7.7	216
46	Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. PLoS Genetics, 2014, 10, e1004741.	3.5	168
47	Î±-Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. Neurodegenerative Diseases, 2014, 14, 1-17.	1.4	39
48	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	7.6	91
49	Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain, 2014, 137, e309-e309.	7.6	101
50	PGC-1Â is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 3477-3484.	2.9	74
51	Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration, 2012, 7, 42.	10.8	708
52	Heatâ€shock protein 70 modulates toxic extracellular Î±â€synuclein oligomers and rescues transâ€synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.5	276
53	Gelsolin co-occurs with Lewy bodies in vivo and accelerates Î±-synuclein aggregation in vitro. Biochemical and Biophysical Research Communications, 2011, 412, 32-38.	2.1	12
54	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced Î±-synuclein oligomers. Journal of Neurochemistry, 2011, 117, 868-878.	3.9	60

#	Article	IF	Citations
55	Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alphaâ€Synuclein as Revealed by Ion Mobility Mass Spectrometry. ChemBioChem, 2011, 12, 2740-2744.	2.6	44
56	Inside Cover: Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry (ChemBioChem 18/2011). ChemBioChem, 2011, 12, 2706-2706.	2.6	0
57	Drug Targets from Genetics: Alpha-Synuclein. CNS and Neurological Disorders - Drug Targets, 2011, 10, 712-723.	1.4	9
58	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent Î±-Synuclein Oligomer Formation and Rescue Î±-Synuclein-Induced Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 849-857.	2.5	162
59	Seeding induced by Î±â€synuclein oligomers provides evidence for spreading of Î±â€synuclein pathology. Journal of Neurochemistry, 2009, 111, 192-203.	3.9	254
60	Single Particle Characterization of Iron-induced Pore-forming Î±-Synuclein Oligomers. Journal of Biological Chemistry, 2008, 283, 10992-11003.	3.4	204
61	Different Species of Î±-Synuclein Oligomers Induce Calcium Influx and Seeding. Journal of Neuroscience, 2007, 27, 9220-9232.	3.6	708
62	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics, 2007, 7, 605-616.	2.2	122
63	Functional protein kinase arrays reveal inhibition of pâ€21â€activated kinase 4 by Î±â€synuclein oligomers. Journal of Neurochemistry, 2007, 103, 2401-2407.	3.9	18